Tyrosine Kinase Inhibitor Discontinuation Safe in Pediatric Chronic Myeloid Leukemia
TKI therapy can be safely discontinued in pediatric patients with chronic-phase CML in sustained deep molecular response.
Source: cancertherapyadvisor.com
📰 Lymphoma Study News
Lymphoma Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lymphoma Study. Real-time updates on events, politics, business and more.
Tyrosine Kinase Inhibitor Discontinuation Safe in Pediatric Chronic Myeloid Leukemia
Study findings suggest TKI therapy can be safely discontinued in pediatric patients with chronic-phase CML in sustained deep molecular response.
University Hospital Medical Information Network Lymphoma Study Group International Scale Pediatric Blood Japan Pediatric Leukemia Lymphoma Study
Source: oncologynurseadvisor.com
NuCana plc: NuCana Announces Update for Phase 3 Biliary Tract Cancer Study
Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373 Continues Rapid Development with Multiple Data Readouts
Source: finanznachrichten.de
Investegate |NuCana plc Announcements | NuCana plc: NuCana Announces Update for Phase 3 Biliary Tract Cancer Study
Investegate announcements from NuCana plc, NuCana Announces Update for Phase 3 Biliary Tract Cancer Study
Source: investegate.co.uk